QuintilesIMS now IQVIA as it aims to ‘outpace the inevitable progress of change’

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/liuzishan)
(Image: Getty/liuzishan)

Related tags: Venture capital

QuintilesIMS next week will officially be rebranded as IQVIA – the newest name in the “Mega-CRO” category created by the rapid and ubiquitous consolidation of the industry.

Equity shares of QuintilesIMS will trade on the NYSE under its new name, IQVIA, and new ticker symbol “IQV” beginning next week.

The name change follows the majority completion of Quintiles/IMS Health integration activates, an IQVIA spokesperson told us. Now, the company is ready to “refocus its attention outward and introduce a new brand to the market.​”

Our new brand sends a clear signal to our clients that we are committed to harnessing advances in technology, analytics and human ingenuity and deliver solutions that will help them innovate with confidence and drive healthcare forward​,” the spokesperson added.

Our vision is to outpace the inevitable progress of change across the life sciences and accelerate our ability to empower healthcare decision makers to meet the future head on​.”

By any other name: The “Mega-CRO”

IMS Health and Quintiles announced the merger in May of last year​, creating one of the world’s largest healthcare information portfolios. Following the announcement, Andrew Schafer, president of Industry Standard Research (ISR) explained​ that the integration​ of both companies’ data would be one of the key success factors of the merge.

Schafer also predicted the pace of change in the CRO industry​ would only increase, with additional mega-mergers rumored. Almost exactly a year later, INC Research and inVentiv announced their merger​, creating one of the largest biopharmaceutical outsourcing providers, and a “top three CRO​,” INC Research CEO Alistair Macdonald told us at the time.

Also this year, Covance acquired Chiltern​ and Parexel was purchased​ by the private equity firm, Pamplona Capital.

In an overview of the CRO market​, Jason Monteleone – now the CEO of Clinipace Worldwide​ – explained that this myriad M&A activity has created a new category of CROs: “Mega,” among them Covance-LabCorp, inVentiv-INC Research, PPD, and QuintilesIMS, which we now know as IQVIA.

The next mega CRO? Monteleone said that “right when you think you know what is coming next, the opposite occurs​” – though a continued interest from private equity​ and an increasing demand for outsourcing​ should keep things interesting.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars